Revenue guidance intact: Despite a 10% Q1 revenue drop, Treace maintained its 2026 forecast of $202M-$212M, expecting growth to return in Q4. Product launches ahead: Q3 commercialization of SuperBite and SpeedXM is set to expand Treace’s market by $300M ...

Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities,

Treace Medical Concepts, Inc. (NASDAQ: TMCI), shares strengthened Friday. The medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities,

PONTE VEDRA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities ...

Treace Medical Concepts, Inc. announced that it will release its financial results for the fourth quarter and full year of 2024 on February 27, 2025, after market close. A conference call with company management will follow at 4:30 pm ET, and interested ...

PONTE VEDRA, Fla., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts (TMCI), Inc. , a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ...

PONTE VEDRA, Fla., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace” or the "Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot ...

Treace Medical Concepts, Inc. has announced the limited market release of its new Percuplasty™ Percutaneous 3D Bunion Correction® System, following successful initial surgical cases. This innovative system aims to enhance bunion surgery with a minimally ...

Q1 2026 Management View "Entering 2026, Treace Medical has evolved beyond its foundation in Lapiplasty into a comprehensive bunion solutions company." (Founder, Chairman & CEO John Treace) "We reported revenue declines of approximately 10% in Q1,